Login
Ricerca |
I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
|
Nuclear medicine in prostate cancer management
EVANGELISTA L.; CECI F.
Copertina flessibile € 42,75
Acquista Preview Email alert
DESCRIZIONE
Prostate cancer imaging has evolved rapidly dur¬ing the last years, moving toward a more person¬alized approach. The comprehensive evaluation of tumor biology alongside the evaluation of different patterns of expression by cancer clones has become an attractive field of investigation for molecular imaging. Next-generation imaging represents a ground-breaking approach, deliver¬ing to patients more accurate diagnostic proce¬dures and leading clinicians to identify specific targets for radioligand therapy. The theragnos¬tic approach-therapy and diagnosis using the same probe-represents, probably, one of the most important innovations in the management of prostate cancer. Hence, the rapid introduction into clinical practice of small molecules bind¬ing prostate-specific membrane antigen (PSMA) represents a brilliant example of how transla¬tional imaging should work. Prostate cancer, as one of the most frequent tumors and causes of death, still represents a hard enemy to fight, but next-generation imaging and radioligand therapy are innovative weapons that might contribute to improve outcomes and quality of life in men affected by the disease.
INDICE DEI CAPITOLI
Background: from chemistry to clinical trials - Different radiopharmaceuticals for imaging and therapy in prostate cancer
Mattia Riondato, Sara Pastorino
Background: from chemistry to clinical trials - The urologist’s point of view: why and when do we need imaging?
Marco Oderda, Paolo Gontero
Background: from chemistry to clinical trials - The oncologist’s point of view: Is there a role for imaging in advanced prostate cancer?
Orazio Caffo
Metabolic radiopharmaceuticals for PET imaging: choline PET and fluciclovine PET - The past and the future of 11C-choline and 18F-choline positron emission tomography/ computed tomography in prostate cancer
Paolo Castellucci, Lorenzo Muraglia, Marco Rensi, Laura Evangelista
Metabolic radiopharmaceuticals for PET imaging: choline PET and fluciclovine PET - Fluciclovine positron emission tomography/ computed tomography for staging and restaging prostate cancer
Cristina Nanni, Lucia Zanoni, Stefano Fanti
Metabolic radiopharmaceuticals for PET imaging: choline PET and fluciclovine PET - Positron emission tomography/magnetic resonance imaging
Paola Mapelli, Ana Maria Samanes Gajate, Maria Picchio
Prostate Specific Membrane Antigen (PSMA) as probe for new generation PET imaging - Prostate-specific membrane antigen-based positron emission tomography imaging for initial diagnosis and staging of prostate cancer
Guido Rovera, Giulia Polverari, Francesco Ceci
Prostate Specific Membrane Antigen (PSMA) as probe for new generation PET imaging - The role of 68Ga-PSMA-11 positron emission tomography in the biochemical recurrence challenge
Federica Matteucci, Paola Caroli
Prostate Specific Membrane Antigen (PSMA) as probe for new generation PET imaging - Fluorine-18 PSMA inhibitors for PET imaging: a step towards perfection?
Riccardo Mei, Andrea Farolfi, Stefano Fanti
The theranostics approach in prostate cancer - PSMA based radio-ligand therapy with beta and alpha emitters in advanced prostate cancer
Stefano Severi, Maddalena Sansovini, Ilaria Grassi, Silvia Nicolini, Anna Sarnelli
The theranostics approach in prostate cancer - Targeted Alpha Therapy (TAT) with 225Ac PSMA
Stefano Severi, Maddalena Sansovini, Ilaria Grassi, Silvia Nicolini, Anna Sarnelli
The theranostics approach in prostate cancer - Gastrin-releasing polypeptide receptor (Bombesin) as new target for imaging and therapy in prostate cancer
Heying Duan, Valentina Ferri, Andrei Iagaru
